Search
Off-Target Effects Episode 5: John Maraganore has been a champion of innovation throughout his career. He discusses the road to success at Alnylam, today's environment, and keeping the U.S. on top
Reflecting on the decades-long journey at Alnylam, John Maraganore describes making it through lean times, and how far oligos and RNAi have come today. Matt asks him about championing true innovation, and what the word 'innovation' even means in today's environment. Plus, his thoughts on China, drug pricing and access, IP, AI ,and more. Chapters Championing innovation - 1:12 Oligos and RNAi today - 5:41 China - 16:20 Me-too and differentiation - 19:11 Drug pricing and access
Apr 9
John Maraganore and Clive Meanwell are launching Corsera Health out of stealth - which, through a combo of predictive diagnostics and an RNAi targeting PCSK9 and angiotensinogen, aims extend lifespans
Launched publicly today, and funded with $50M at this point, Corsera Health hopes to target those who are most at risk for...
Sep 2, 2025
John Maraganore shares his take on biotech in 2025 and discusses the science behind his recently launched RNAi company, City Therapeutics
He gives an optimistic take on the sector, describes why he thinks policy reforms can be positive but should be done strategically and...
Feb 11, 2025
Reviewing the state of biotech with John Maraganore
John Maraganore shares his thoughts about biotech's big achievements in 2023 and what to watch in 2024.
Dec 29, 2023
.png){kind=logo}
